# Sepax Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sepax-technologies

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.sepax-tech.com.cn
- Total disclosed funding: $109M
- Latest round: Series D (Nov 15, 2021)
- Investors on record: 11

## About

Established in 2002, based in Suzhou, China and headquartered in Delaware, US, Sepax Technologies, Inc. operates as a biotechnology company which focuses on chromatographic separation science and liquid chromatography packing. The company is mainly involved in the field of analytical chromatography, industrial purification and medical diagnosis. In November 2021, the firm raised CNY 500 million in series E funding. In January 2025, the company was listed on the Shanghai Sci-Tech Innovation Board. Its stock code is 688758.

The company self-developed analytical chromatography products include size exclusion chromatography column, ion exchange chromatography column, affinity chromatography column, hydrophobic chromatography column, hydrophobic reverse phase chromatography column, polymer reverse phase chromatography column, silica gel reverse phase chromatography column, other silica gel chromatography column, pharmacopoeia special column, solid phase extraction cartridges, chromatographic accessories and chromatographic column test standards. Besides, the industrial purification products include affinity fillers, composite chromatography fillers, ion exchange fillers, size exclusion fillers, hydrophobic fillers, silica matrix fillers, polymer reversed phase fillers, other silica matrix fillers and FPLC (Fast protein liquid chromatography) chromatography column tubes.

The company’s revenue is generated by providing liquid chromatography fillers, analytical testing liquid chromatography columns and consumables.

In the future, the company will build a research and development center and launch a 200,000 liters/year auxiliary materials project for biopharmaceutical separation and purification.

## Funding rounds

- Series D, Nov 15, 2021, $78M — CPE Funds Management, Hillhouse Investment, Gan & Lee Pharmaceutical, Ltd., Shanghai Jianyi Private Equity Fund Management, Sinovac Biotech Co. Ltd., Sherpa Healthcare Partners, GL Ventures
- Series C, Mar 8, 2021, $31M — Fosun International, China Life Capital
- Series A, Jun 11, 2018 — Huatai Zijin Investment
- Angel, Nov 24, 2015 — Comway Capital

## Investors

- Comway Capital (https://capitalatlas.ai/funds/comway-capital) — Angel
- Huatai Zijin Investment (https://capitalatlas.ai/funds/huatai-zijin-investment) — Series A
- Fosun International (https://capitalatlas.ai/funds/fosun-international) — Series C
- China Life Capital — Series C
- CPE Funds Management (https://capitalatlas.ai/funds/cpe-funds-management) — Series D
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series D
- Gan & Lee Pharmaceutical, Ltd. — Series D
- Shanghai Jianyi Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-jianyi-private-equity-fund-management) — Series D
- Sinovac Biotech Co. Ltd. — Series D
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series D
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series D